BrainStorm

Autologous Stem Cell Therapeutics for Neurodegenerative Disorders

Health Tech & Life Sciences
Public on NASDAQ on Oct 2003

Company Overview

Snapshot

Founded in January 2000, BrainStorm operates with 11–50 employees and has raised a total of $67.13 million across 17 funding rounds. The company went public on NASDAQ in October 2003, marking a significant milestone in its journey to develop autologous stem cell therapeutics.

Business overview

BrainStorm Cell Therapeutics is a biotechnology company focused on pioneering treatments for neurodegenerative diseases, specifically amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). The company's core technology, NurOwn®, involves transforming autologous mesenchymal stem cells into neurotrophic factor-secreting cells to deliver growth factors directly to affected areas. BrainStorm serves the healthcare and life sciences sectors, targeting patients and providers within the neurology and therapeutics markets.

Strategic signal

In October 2023, BrainStorm Cell Therapeutics announced a strategic realignment to prioritize the development of NurOwn® for ALS treatment, following an FDA advisory committee meeting to review the therapy. This indicates a focused effort to advance its lead product, signaling to investors a clear strategic direction despite regulatory challenges.

Company Intelligence Q&A

What was the outcome of the FDA advisory committee meeting regarding NurOwn® for ALS?
In September 2023, FDA advisers voted against recommending approval of NurOwn®, BrainStorm Cell Therapeutics' experimental ALS treatment.
What strategic decision did BrainStorm Cell Therapeutics make in October 2023?
In October 2023, BrainStorm Cell Therapeutics announced a strategic realignment, prioritizing the development of NurOwn® for the treatment of ALS.
When did BrainStorm Cell Therapeutics go public?
BrainStorm Cell Therapeutics went public on NASDAQ in October 2003.
What was a key development for NurOwn® in Japan?
In September 2020, BrainStorm announced the grant of a new Japanese patent for NurOwn®, expanding its intellectual property portfolio.
What was a significant grant received by BrainStorm Cell Therapeutics in 2020?
In April 2020, BrainStorm was awarded a non-dilutive grant by the Israel Innovation Authority.

External links